Heightened Efficacy of Anidulafungin When Used in Combination with Manogepix or 5-Flucytosine against Candida auris In Vitro
Antimicrobial Agents and Chemotherapy · 2023
DOI: 10.1128/aac.01645-22 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Larissa L H John und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Council Centre for Medical Mycology, University of Exeter, Geoffrey Pope Building, Stocker Road, Exeter, United Kingdom. Hauptthemen laut MEDLINE: Antifungal Agents, Flucytosine. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: MRF_, Medical Research Council, Biotechnology and Biological Sciences Research Council.
Abstract (Originalsprache)
Candida auris is an emerging, multidrug-resistant fungal pathogen that causes refractory colonization and life-threatening, invasive nosocomial infections. The high proportion of C. auris isolates that display antifungal resistance severely limits treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Research Council Centre for Medical Mycology, University of Exeter, Geoffrey Pope Building, Stocker Road, Exeter, United Kingdom.
- Institute of Infection and Immunity, St George's University of London, Cranmer Terrace, London, United Kingdom.
- Clinical Academic Group in Infection and Immunity, St George's University Hospitals NHS Foundation Trust, Cranmer Terrace, London, United Kingdom.
- Division of Infectious Diseases, Medical University of Graz, Austria.
- BioTechMed, Graz, Austria.
- Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz, Austria.
ORCID-Profile: Larissa L H John, Tihana Bicanic, Alistair J P Brown, Elaine M Bignell
Förderung
- MRF_
- Medical Research Council
- Biotechnology and Biological Sciences Research Council
- Medical Research Foundation UK
- Medical Research Council Centre for Medical Mycology
- UKRI | Biotechnology and Biological Sciences Research Council
- UKRI | Medical Research Council
- UKRI | Medical Research Council (MRC) Doctoral Training Grant
Zitieren
APA
John, L. L. H., Thomson, D. D., Bicanic, T., Hoenigl, M., Brown, A. J. P., Harrison, T. S., & Bignell, E. M. (2023). Heightened Efficacy of Anidulafungin When Used in Combination with Manogepix or 5-Flucytosine against Candida auris In Vitro. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01645-22
Vancouver
John LLH, Thomson DD, Bicanic T, Hoenigl M, Brown AJP, Harrison TS, et al. Heightened Efficacy of Anidulafungin When Used in Combination with Manogepix or 5-Flucytosine against Candida auris In Vitro. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.01645-22
BibTeX
@article{John2023,
author = {John, Larissa L H and Thomson, Darren D and Bicanic, Tihana and Hoenigl, Martin and Brown, Alistair J P and Harrison, Thomas S and Bignell, Elaine M},
title = {Heightened Efficacy of Anidulafungin When Used in Combination with Manogepix or 5-Flucytosine against Candida auris In Vitro},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2023},
doi = {10.1128/aac.01645-22}
}
EUVIMED